We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma.
- Authors
Ueshima, Kazuomi; Kudo, Masatoshi; Takita, Masahiro; Nagai, Tomoyuki; Tatsumi, Chie; Ueda, Taisuke; Kitai, Satoshi; Ishikawa, Emi; Yada, Norihisa; Inoue, Tatsuo; Hagiwara, Satoru; Minami, Yasunori; Chung, Hobyung; Sakurai, Toshiharu
- Abstract
Objective: The purpose of this study was to evaluate the role of des-γ-carboxyprothrombin (DCP) as a marker for the efficacy of sorafenib therapy for hepatocellular carcinoma (HCC). Methods: Patients with advanced HCC treated with sorafenib were retrospectively evaluated, focusing on DCP levels and clinical characteristics. Results: 50 patients with advanced HCC were treated with sorafenib alone. In 25 of these patients, the serum levels of DCP were evaluated twice (pretreatment and within 2 weeks after starting therapy). The time to progression was significantly longer in patients in whom the DCP level at 2 weeks after starting sorafenib was ≥2-fold higher than the pretreatment levels, as compared with patients without an increase in DCP (p = 0.0296). Conclusions: The serum level of DCP is a surrogate marker for tissue hypoxia and can be a predictive marker to assess the tumor response to sorafenib therapy. Copyright © 2011 S. Karger AG, Basel
- Publication
Digestive Diseases, 2011, Vol 29, Issue 3, p321
- ISSN
0257-2753
- Publication type
Article
- DOI
10.1159/000327570